Marina Celanovic

489 total citations
18 papers, 126 citations indexed

About

Marina Celanovic is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marina Celanovic has authored 18 papers receiving a total of 126 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Marina Celanovic's work include Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Marina Celanovic is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Marina Celanovic collaborates with scholars based in United States, France and Czechia. Marina Celanovic's co-authors include Sarat Chandarlapaty, Aditya Bardia, Mario Campone, Hannah M. Linden, Gary A. Ulaner, Vasiliki Pelekanou, Gautier Paux, Patrick Cohen, Nils Ternès and Jeffrey E. Ming and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Marina Celanovic

15 papers receiving 123 citations

Peers

Countries citing papers authored by Marina Celanovic

Since Specialization

Citations

This map shows the geographic impact of Marina Celanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Celanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Celanovic more than expected).

Fields of papers citing papers by Marina Celanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Celanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Celanovic. The network helps show where Marina Celanovic may publish in the future.

Co-authorship network of co-authors of Marina Celanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Celanovic. A scholar is included among the top collaborators of Marina Celanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Celanovic. Marina Celanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial 2025 ·Journal of Thoracic Oncology ·(unknown), L. Paz-Ares, Hakan Harputluoğlu, (unknown), Sérgio Rossi, (unknown), Carole Hélissey, (unknown), (unknown), Mehmet Alı Nahıt Şendur, M. D’Arcangelo, (unknown), (unknown), Özgür Özyılkan, (unknown), Marina Celanovic, (unknown), (unknown)	0
2	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer 2022 ·Nature Communications ·Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, (unknown), (unknown), Patrick Cohen, (unknown), Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone	40
3	Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer 2022 ·Cancer Research ·Mario Campone, Sarat Chandarlapaty, Aditya Bardia, Patrick Neven, Katarína Petráková, (unknown), Valentina Boni, Sofía Braga, Marina Celanovic, Patrick Cohen, (unknown), (unknown), Vasiliki Pelekanou, Hannah M. Linden	1
4	Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer 2022 ·Cancer Research ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, (unknown), Sofía Braga, Valentina Boni, (unknown), Marina Celanovic, Patrick Cohen, Gautier Paux, Vasiliki Pelekanou, Nils Ternès, Joon Sang Lee, Mario Campone	6
5	Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women 2022 ·Cancer Research ·Hiroji Iwata, Aditya Bardia, Simon Lord, Hannah M. Linden, Mario Campone, (unknown), Kan Yonemori, Toru Mukohara, Cécile Combeau, Nils Ternès, (unknown), (unknown), Joon Sang Lee, Marina Celanovic, Anne-Laure Bauchet, Monsif Bouaboula, Tomoyuki Tanaka, Yumiko Kawabata, Sarat Chandarlapaty	1
6	Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer 2022 ·Cancer Research ·Mario Campone, Patrick Neven, Katarína Petráková, Sofía Braga, Marina Celanovic, Patrick Cohen, (unknown), (unknown), Vasiliki Pelekanou, Valentina Boni	1
7	AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). 2021 ·Journal of Clinical Oncology ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, Peter Kabos, Sofía Braga, Valentina Boni, (unknown), (unknown), (unknown), Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone	13
8	264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) 2021 ·Annals of Oncology ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, Peter Kabos, Sofía Braga, Valentina Boni, Vasiliki Pelekanou, Nils Ternès, (unknown), Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone	3
9	Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD 2021 ·Cancer Research ·Maysoun Shomali, Fangxian Sun, Laurent Besret, Anne Caron, Joon Sang Lee, (unknown), Laurent Schio, Jack Pollard, Vasiliki Pelekanou, Patrick Cohen, Marina Celanovic, Christina I. Herold, (unknown), Laurent Debüssche, Monsif Bouaboula	0
10	Abstract PD8-08: A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1 2021 ·Cancer Research ·Hannah M. Linden, Mario Campone, Aditya Bardia, Gary A. Ulaner, (unknown), (unknown), Vasiliki Pelekanou, Marina Celanovic, Sarat Chandarlapaty	11
11	277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study 2020 ·Annals of Oncology ·Sarat Chandarlapaty, Aditya Bardia, Simon Lord, Hannah M. Linden, Vasiliki Pelekanou, Nils Ternès, Jeffrey E. Ming, Valérie Boutet, Eric Boitier, (unknown), (unknown), (unknown), Alexei Protopopov, Marina Celanovic, (unknown), Mario Campone	3
12	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study 2020 ·Cancers ·Ian Chau, Marwan Fakih, Pilar García‐Alfonso, Zdeněk Linke, Ana Ruiz‐Casado, (unknown), (unknown), Marina Celanovic, Thomas H. Cartwright	13
13	Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). 2020 ·Journal of Clinical Oncology ·Mario Campone, Aditya Bardia, Gary A. Ulaner, Sarat Chandarlapaty, (unknown), (unknown), Vasiliki Pelekanou, Marina Celanovic, Hannah M. Linden	7
14	Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer 2020 ·Cancer Research ·Mario Campone, Aditya Bardia, Gary A. Ulaner, Sarat Chandarlapaty, (unknown), (unknown), Jeffrey E. Ming, Marina Celanovic, Hannah M. Linden	4
15	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor 2019 ·Bone Marrow Transplantation ·Curly Morris, Christian Chabannon, Tamás Masszi, Nigel H. Russell, Hareth Nahi, Guido Kobbe, Marta Krejčí, Holger W. Auner, David Pohlreich, Patrick Hayden, Grzegorz Basak, Stig Lenhoff, Nicolaas Schaap, Anja van Biezen, (unknown), Simona Iacobelli, Qianying Liu, Marina Celanovic, Laurent Garderet, Nicolaus Kröger	10
16	Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer. 2019 ·Journal of Clinical Oncology ·Aditya Bardia, Hannah M. Linden, Gary A. Ulaner, Sarat Chandarlapaty, (unknown), Marina Celanovic, Mario Campone	0
17	Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). 2019 ·Journal of Clinical Oncology ·Aditya Bardia, Hannah M. Linden, Gary A. Ulaner, Sarat Chandarlapaty, (unknown), (unknown), Marina Celanovic, Mario Campone	5
18	A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor 2018 ·Biology of Blood and Marrow Transplantation ·Hareth Nahi, Marina Celanovic, Qianying Liu, Johan Lund, Valdas Pečeliūnas	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact